Search research articles
Contact Us
Filters
Showing results (11-20 of 121) with videos related to
Page
of 13
Sort By:
F1000Research
|
August 28, 2020
Development of vaccines for SARS-CoV-2
Wern Hann Ng, Xiang Liu, Suresh Mahalingam
The Journal of Infectious Diseases
|
May 23, 2019
Inhibition of Interleukin 1β Signaling by Anakinra Ameliorates Proinflammatory Cytokine Responses in Zika Virus-Infected Human Blood-Brain Barrier Endothelial Cells
Linda Hueston, Georges E Grau, Suresh Mahalingam
Bio-Protocol
|
March 3, 2021
Analysis of Functional Virus-generated PAMP RNAs Using IFNα/β ELISA Assay
Margit Mutso, Xiang Liu, Andres Merits, et al.
Emerging Infectious Diseases
|
July 24, 2013
Call to action for dengue vaccine failure
Suresh Mahalingam, Belinda L Herring, Scott B Halstead
The Journal of General Virology
|
February 29, 2024
Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials
Shambhavi Rao, Daniel Erku, Suresh Mahalingam, et al.
The Lancet. Infectious Diseases
|
June 28, 2017
Zika enhancement: a reality check
Suresh Mahalingam, Mauro M Teixeira, Scott B Halstead
The Lancet. Infectious Diseases
|
September 4, 2015
Emergent chikungunya virus and arthritis in the Americas
Michael S Rolph, Suan Sin Foo, Suresh Mahalingam
Journal of Virology
|
January 28, 2026
The ability of alphavirus replicases to synthesize non-viral type I interferon-inducing RNAs correlates with viral RNA synthesis and has a diverse impact on virus replication and pathogenicity
Ailar Omler, Anna Rutmane, Suresh Mahalingam, et al.
The Lancet. Infectious Diseases
|
February 23, 2013
Dengue vaccine efficacy trial: does interference cause failure?
Sathyamangalam Swaminathan, Navin Khanna, Belinda Herring, et al.
Journal of Medicinal Chemistry
|
October 2, 2013
Chikungunya virus: emerging targets and new opportunities for medicinal chemistry
Adel A Rashad, Suresh Mahalingam, Paul A Keller
Page
of 13
Search research articles
Search
Showing results (11-20 of 121) with videos related to
Sort By:
Page
of 13
F1000Research
|
August 28, 2020
Development of vaccines for SARS-CoV-2
Wern Hann Ng, Xiang Liu, Suresh Mahalingam
The Journal of Infectious Diseases
|
May 23, 2019
Inhibition of Interleukin 1β Signaling by Anakinra Ameliorates Proinflammatory Cytokine Responses in Zika Virus-Infected Human Blood-Brain Barrier Endothelial Cells
Linda Hueston, Georges E Grau, Suresh Mahalingam
Bio-Protocol
|
March 3, 2021
Analysis of Functional Virus-generated PAMP RNAs Using IFNα/β ELISA Assay
Margit Mutso, Xiang Liu, Andres Merits, et al.
Emerging Infectious Diseases
|
July 24, 2013
Call to action for dengue vaccine failure
Suresh Mahalingam, Belinda L Herring, Scott B Halstead
The Journal of General Virology
|
February 29, 2024
Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials
Shambhavi Rao, Daniel Erku, Suresh Mahalingam, et al.
The Lancet. Infectious Diseases
|
June 28, 2017
Zika enhancement: a reality check
Suresh Mahalingam, Mauro M Teixeira, Scott B Halstead
The Lancet. Infectious Diseases
|
September 4, 2015
Emergent chikungunya virus and arthritis in the Americas
Michael S Rolph, Suan Sin Foo, Suresh Mahalingam
Journal of Virology
|
January 28, 2026
The ability of alphavirus replicases to synthesize non-viral type I interferon-inducing RNAs correlates with viral RNA synthesis and has a diverse impact on virus replication and pathogenicity
Ailar Omler, Anna Rutmane, Suresh Mahalingam, et al.
The Lancet. Infectious Diseases
|
February 23, 2013
Dengue vaccine efficacy trial: does interference cause failure?
Sathyamangalam Swaminathan, Navin Khanna, Belinda Herring, et al.
Journal of Medicinal Chemistry
|
October 2, 2013
Chikungunya virus: emerging targets and new opportunities for medicinal chemistry
Adel A Rashad, Suresh Mahalingam, Paul A Keller
Page
of 13